Combination therapy for obesity and metabolic disease.
OBJECTIVE
There is a growing interest in developing combination therapies for treatment and management of obesity and related metabolic diseases.


RESULTS
Emerging data from recently completed and ongoing randomized clinical trials suggest that certain combination-drug therapies in development have greater efficacy than currently available single-drug therapies in terms of achieved weight loss and reduction in risk factors.


CONCLUSIONS
Combination-drug therapy may have a role in the treatment of obesity and related diseases as well as for prevention of risk factors. As we await safety data from studies with larger samples, the demonstrated efficacy of some of the combination drug therapies in late-stage development appears to be robust and clinically meaningful.
Gadde
Kishore M
KM
Obesity Clinical Trials Programme, Duke University Medical Centre, Durham, North Carolina 27710, USA.
Allison
David B
DB
D019440:Anti-Obesity Agents / Q000008:administration & dosage*; D004338:Drug Combinations; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D008659:Metabolic Diseases / Q000188:drug therapy*; D009765:Obesity / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods
D019440:Anti-Obesity Agents; D004338:Drug Combinations; D007004:Hypoglycemic Agents